Humana Inc. (NYSE:HUM) Holdings Raised by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA boosted its stake in Humana Inc. (NYSE:HUM) by 59.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 624,756 shares of the insurance provider’s stock after acquiring an additional 233,099 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Humana were worth $158,507,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of HUM. FPC Investment Advisory Inc. bought a new position in shares of Humana in the fourth quarter valued at approximately $27,000. Centricity Wealth Management LLC bought a new position in Humana during the 4th quarter valued at $30,000. LFA Lugano Financial Advisors SA increased its position in shares of Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Humana in the fourth quarter valued at $33,000. Finally, Atwood & Palmer Inc. boosted its stake in Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. dropped their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 target price on shares of Humana in a report on Wednesday, February 12th. StockNews.com cut shares of Humana from a “buy” rating to a “hold” rating in a report on Tuesday, March 18th. Truist Financial upped their price target on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Finally, Barclays raised their price objective on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Eighteen analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Humana presently has an average rating of “Hold” and an average target price of $280.17.

Humana Stock Performance

Shares of HUM opened at $253.37 on Friday. The company has a market capitalization of $30.58 billion, a PE ratio of 25.46, a PEG ratio of 2.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The company’s 50 day moving average price is $267.58 and its 200 day moving average price is $272.13. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Research analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.40%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio (DPR) is presently 35.58%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.